Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective-Reference-Cited by-同舟云学术

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective

Published:2022-06-21 Issue:3 Volume:112 Page:501-526
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Chu Xiaoyan¹^ORCID,Prasad Bhagwat²^ORCID,Neuhoff Sibylle³^ORCID,Yoshida Kenta⁴^ORCID,Leeder James Steven⁵^ORCID,Mukherjee Dwaipayan⁶^ORCID,Taskar Kunal⁷^ORCID,Varma Manthena V. S.⁸^ORCID,Zhang Xinyuan⁹,Yang Xinning⁹^ORCID,Galetin Aleksandra¹⁰^ORCID

Affiliation:

1. Department of ADME and Discovery Toxicology Merck & Co., Inc. Kenilworth New Jersey USA

2. Department of Pharmaceutical Sciences Washington State University Spokane Washington USA

3. Certara UK Ltd. Sheffield UK

4. Clinical Pharmacology, Genentech Research and Early Development South San Francisco California USA

5. Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation Children’s Mercy Kansas City Kansas City Missouri USA

6. Clinical Pharmacology & Pharmacometrics, Research & Development AbbVie, Inc. North Chicago Illinois USA

7. DMPK, IVIVT, GlaxoSmithKline R&D Stevenage UK

8. Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Worldwide R&D Pfizer Inc Groton Connecticut USA

9. Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration Silver Spring Maryland USA

10. Centre for Applied Pharmacokinetic Research, School of Health Sciences The University of Manchester Manchester UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2643

Reference125 articles.

1. Membrane transporters in drug development

2. Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

3. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro , Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

4. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier;Drug Metabolism Reviews;2024-07-05

2. The Competitive Counterflow Assay for Identifying Drugs Transported by Solute Carriers: Principle, Applications, Challenges/Limits, and Perspectives;European Journal of Drug Metabolism and Pharmacokinetics;2024-07-03

3. Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges;Clinical Pharmacokinetics;2024-06-18

4. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?;Journal of Pharmaceutical Sciences;2024-06

5. Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof‐of‐Concept Application of Liquid Biopsy in Renal Impairment;Clinical Pharmacology & Therapeutics;2024-05-13